Brian Skorney
Stock Analyst at Baird
(3.32)
# 944
Out of 5,182 analysts
119
Total ratings
43.53%
Success rate
4.05%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Outperform | $22 → $41 | $22.42 | +82.87% | 5 | Mar 18, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $63 → $97 | $56.45 | +71.83% | 2 | Mar 9, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $93.17 | -5.55% | 6 | Dec 9, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $22.80 | -34.21% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $35.95 | +72.46% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $10.00 | +420.00% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $130.24 | +42.81% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $39.29 | +207.97% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $18.23 | +75.58% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $176.67 | +44.34% | 17 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $652 → $587 | $749.39 | -21.67% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $138.86 | -27.98% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $10.91 | +174.98% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $12.99 | +53.96% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $23.45 | +6.61% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $346.47 | -37.95% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.67 | +394.26% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.43 | +362.63% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $437.56 | -25.72% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $24.80 | -59.68% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.59 | +45,301.04% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.86 | +55.44% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $0.55 | +54,445.45% | 3 | May 7, 2018 |
Alto Neuroscience
Mar 18, 2026
Maintains: Outperform
Price Target: $22 → $41
Current: $22.42
Upside: +82.87%
Xenon Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $63 → $97
Current: $56.45
Upside: +71.83%
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $93.17
Upside: -5.55%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $22.80
Upside: -34.21%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $35.95
Upside: +72.46%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $10.00
Upside: +420.00%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $130.24
Upside: +42.81%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $39.29
Upside: +207.97%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $18.23
Upside: +75.58%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $176.67
Upside: +44.34%
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $749.39
Upside: -21.67%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $138.86
Upside: -27.98%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $10.91
Upside: +174.98%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $12.99
Upside: +53.96%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $23.45
Upside: +6.61%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $346.47
Upside: -37.95%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.67
Upside: +394.26%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.43
Upside: +362.63%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $437.56
Upside: -25.72%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $24.80
Upside: -59.68%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.59
Upside: +45,301.04%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.86
Upside: +55.44%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $0.55
Upside: +54,445.45%